Clene (CLNNW) Stock Analysis

What Clene does

Clene Inc. is a clinical-stage pharmaceutical firm dedicated to the discovery, development, and market introduction of innovative therapeutic agents derived from clean-surfaced nanotechnology (CSN). The company's primary drug candidate, CNM-Au8, is currently undergoing extensive clinical evaluation for various neurological conditions. For Amyotrophic Lateral Sclerosis (ALS), it's being tested in a pivotal Phase 2/3 registrational clinical trial, building on a previously completed Phase 2 "proof-of-concept" study in patients with early symptomatic ALS. Further research includes two finished open-label, investigator-blinded Phase 2 trials that explored its effects on brain energy metabolites. CNM-Au8 has also completed a Phase 2 trial focused on addressing visual pathway deficits in chronic optic neuropathy, aiming to promote remyelination in individuals with stable relapsing Multiple Sclerosis. Another Phase 2 trial is also targeting Parkinson's Disease patients. Beyond its flagship candidate, Clene's portfolio features CNM-AgZn17, a gel polymer suspension containing silver and zinc ions, which is under development for treating infectious diseases and supporting wound healing. Additionally, the company offers CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent designed to combat various infections, including conditions like COVID-19, and to bolster immune responses for symptom relief. Clene also markets and distributes dietary supplements, specifically rMetx, a liquid supplement featuring zinc-silver ions, and KHC46, a liquid gold supplement with ultra-low concentrations of gold nanoparticles. The company maintains its headquarters in Salt Lake City, Utah.

Key metrics

ETFs linked to CLNNW

Broad-market and Healthcare sector ETFs an investor holding Clene is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CLNNW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Clene?

Clene trades under the ticker CLNNW on NASDAQ.

Which exchange is CLNNW listed on?

CLNNW is listed on NASDAQ.

What sector does Clene operate in?

Clene is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CLNNW in a portfolio?

PortView shows CLNNW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.